Arrowhead Pharmaceuticals trades near $70 support amid conference participation and weak momentum

Traders Union
All News
Companies
Arrowhead Pharmaceuticals slides 3.44% today

Highlights

ARWR trades below short- and medium-term moving averages, indicating near-term selling pressure despite a strong long-term uptrend.
Momentum and oscillators show a bearish bias with weak trend strength, as the price remains near the bottom of its weekly range.
The expected price range for the coming week is $69.00–$74.10, with a high probability of sideways consolidation above key support.

Short-term selling and long-term bullish bias as price tests resistance

ARWR is currently trading at $70.81, below the MA-20 ($75.83) and MA-50 ($72.04), but well above the MA-200 ($56.21). This configuration indicates the price is undergoing short-term and medium-term selling pressure but remains bullish on the long-term structure. The Ichimoku Kijun at $75.78 serves as immediate resistance. Near-term support is marked by the MA-50 at $72.04, with key support at the MA-100 ($67.48). Resistance is nearby at the MA-20 ($75.83), and stronger resistance sits at the Ichimoku Kijun ($75.78).

Bearish momentum and fading strength as weekly losses accelerate

Momentum on D1 is soft, with the MACD signaling neutrality and the ADX at a weak 16.18, suggesting a lack of clear trend direction. Oscillators paint a bearish bias: RSI stands at 48 and points to selling, Stoch RSI is at 31.73 and signals to sell, and CCI at -82.27 underscores loss of upward momentum. BBP signals an overbought condition ($1.73), implying lingering recent buyer dominance but fading strength. The Awesome Oscillator is neutral and does not reinforce the current move. ARWR has fallen $2.28 (3.04%) this week from the previous close of $73.09, currently positioned at the bottom of its weekly range. Weekly volatility stands at 9.31%. The price action shows a steady decline from the high, aligned with near-term indicator weakness. In today's session, the stock lost 3.44%, marking heightened downside momentum.

High upside probability as sideways consolidation supports uptrend

For the coming week, the expected price range is $69.00 to $74.10, referencing both short-term volatility and the provided forecast, and keeps ARWR within reach of its recent 52-week high at $82.26. The probability of a price increase is very high (more than 80%), given all major W1 indicators (MA-50, RSI, ADX, MACD) signal "Buy" or "Strong Buy." A decrease is less likely. The baseline scenario is continued sideways consolidation within the $69.00–$74.10 range. A bullish break above $74.10 would turn focus toward retesting year-to-date highs. Conversely, a drop below $69.00 opens the door to a pullback toward the $67.50 area, in line with medium-term support. This range remains well above the 52-week low ($14.30), highlighting the strength of ARWR’s longer-term uptrend.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Arrowhead Pharmaceuticals received FDA approval for a new therapy targeting adults with Familial Chylomicronemia Syndrome. With evolving developments, investors should monitor how further regulatory progress and market uptake could impact Arrowhead's longer-term momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.